2024-02-09 08:38:00
Lilly’s Tirzépatide advances on MASH
Lilly communicated on phase II results on MASH (formerly called NASH), concerning tirzepatide, its GLP-1 analogue, already approved for diabetes and obesity. The drug met its primary endpoint, as 74% of study participants, following one year of treatment at the highest dose (15 mg), achieved disappearance of MASH and no worsening of fibrosis, compared to 13% for the placebo.
I will tell you
source
Le Nipocalimab valid sa phase III
NOT A WORD achieved positive results on autoimmune myasthenia gravis with nipocalimab. In a pivotal phase III trial, the monoclonal antibody met its primary endpoint, with a statistically significant reduction in the Garches Myasthenic Score, which is used to assess disease severity. Nipocalimab also obtained positive results, this time in phase II, on Sjögren’s syndrome, an autoimmune disease causing dry mouth and eyes.
Positive phase III for Vertex on cystic fibrosis
Vertex announced positive results for its treatment combining vanzacaftor, tezacaftor and deutivacaftor. During a pivotal phase III study in cystic fibrosis, the combination was not shown to be inferior to Trikafta (elexacaftor, ivacaftor, tezacaftor) from the same laboratory, in improving the respiratory function of patients. It has even been shown to be superior in reducing salt levels in sweat, one of the markers of the disease. Vertex anticipates an application for authorization in the United States later this year.
Selected for you
1707673967
#pipeline #Lilly #Vertex
